← Inner Mongolia Yili Industrial overview

Inner Mongolia Yili Industrial vs CSPC Innovation Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Inner Mongolia Yili Industrial Group Co Ltd (600887.CG)

Q3 2026
▲3▼1

Yili's profit slump offset by buyback and raw milk recovery

  • First-half profit drops 20%, Q2 collapses Yili's first-half net profit fell 20% to 5.76 billion yuan, with second-quarter profit down 84% year-on-year and 93% quarter-on-quarter. Revenue rose 4.1%, but the profit plunge shows margins are under heavy pressure, which weighs on the stock price.

    This is the biggest new negative force on the stock and directly explains why it may be moving down.

  • 1–2 billion yuan buyback for cancellation Yili plans to buy back 1–2 billion yuan of its own shares and cancel them, reducing the number of shares outstanding. This supports the share price by boosting earnings per share and signals management's confidence in the company's future.

    This is a major new positive capital action that directly supports the stock price and offsets the profit miss.

  • Raw milk cycle turning, dairy stocks rally The dairy cow herd is shrinking fast, and raw milk prices are rising in many regions. This supply tightening is starting to reverse the long downcycle, which should improve profits for dairy leaders like Yili as selling prices recover.

    This is a new industry-level driver that could lift Yili's future earnings and explains positive sector sentiment.

  • Yili showcases innovation and data hub at World Dairy Congress Yili hosted the 2026 World Dairy Congress, launched a global dairy data hub, and unveiled ten innovations. This reinforces its industry leadership and long-term technology edge, which can support the stock by improving growth prospects.

    This is a new event that highlights Yili's strategic positioning and innovation, a positive long-term driver.

August 2026
▲3▼1

Yili's profit slump offset by buyback and raw milk recovery

  • First-half profit drops 20%, Q2 collapses Yili's first-half net profit fell 20% to 5.76 billion yuan, with second-quarter profit down 84% year-on-year and 93% quarter-on-quarter. Revenue rose 4.1%, but the profit plunge shows margins are under heavy pressure, which weighs on the stock price.

    This is the biggest new negative force on the stock and directly explains why it may be moving down.

  • 1–2 billion yuan buyback for cancellation Yili plans to buy back 1–2 billion yuan of its own shares and cancel them, reducing the number of shares outstanding. This supports the share price by boosting earnings per share and signals management's confidence in the company's future.

    This is a major new positive capital action that directly supports the stock price and offsets the profit miss.

  • Raw milk cycle turning, dairy stocks rally The dairy cow herd is shrinking fast, and raw milk prices are rising in many regions. This supply tightening is starting to reverse the long downcycle, which should improve profits for dairy leaders like Yili as selling prices recover.

    This is a new industry-level driver that could lift Yili's future earnings and explains positive sector sentiment.

  • Yili showcases innovation and data hub at World Dairy Congress Yili hosted the 2026 World Dairy Congress, launched a global dairy data hub, and unveiled ten innovations. This reinforces its industry leadership and long-term technology edge, which can support the stock by improving growth prospects.

    This is a new event that highlights Yili's strategic positioning and innovation, a positive long-term driver.

Latest
▲3▼1

Yili's profit slump offset by buyback and raw milk recovery

  • First-half profit drops 20%, Q2 collapses Yili's first-half net profit fell 20% to 5.76 billion yuan, with second-quarter profit down 84% year-on-year and 93% quarter-on-quarter. Revenue rose 4.1%, but the profit plunge shows margins are under heavy pressure, which weighs on the stock price.

    This is the biggest new negative force on the stock and directly explains why it may be moving down.

  • 1–2 billion yuan buyback for cancellation Yili plans to buy back 1–2 billion yuan of its own shares and cancel them, reducing the number of shares outstanding. This supports the share price by boosting earnings per share and signals management's confidence in the company's future.

    This is a major new positive capital action that directly supports the stock price and offsets the profit miss.

  • Raw milk cycle turning, dairy stocks rally The dairy cow herd is shrinking fast, and raw milk prices are rising in many regions. This supply tightening is starting to reverse the long downcycle, which should improve profits for dairy leaders like Yili as selling prices recover.

    This is a new industry-level driver that could lift Yili's future earnings and explains positive sector sentiment.

  • Yili showcases innovation and data hub at World Dairy Congress Yili hosted the 2026 World Dairy Congress, launched a global dairy data hub, and unveiled ten innovations. This reinforces its industry leadership and long-term technology edge, which can support the stock by improving growth prospects.

    This is a new event that highlights Yili's strategic positioning and innovation, a positive long-term driver.

CSPC Innovation Pharmaceutical Co Ltd Class A (300765.CS)

Q3 2026
▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

  • Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.

    The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.

  • SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.

    This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.

  • Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.

    These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

August 2026
▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

  • Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.

    The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.

  • SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.

    This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.

  • Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.

    These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

Latest
▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

  • Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.

    The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.

  • SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.

    This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.

  • Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.

    These regulatory and clinical steps expand the pipeline and signal more near-term product launches.